• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质母细胞瘤中 O6-甲基鸟嘌呤-DNA 甲基转移酶、P-糖蛋白和多药耐药蛋白 1 的免疫组织化学表达的预后意义。

Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.

机构信息

Department of Neurosurgery, Faculty of Medical Sciences, University of Fukui, Yoshida-gun, Fukui, Japan.

出版信息

Neuropathology. 2009 Aug;29(4):379-88. doi: 10.1111/j.1440-1789.2008.00983.x. Epub 2008 Nov 19.

DOI:10.1111/j.1440-1789.2008.00983.x
PMID:19019175
Abstract

We studied the expression of O(6)-methylguanine-DNA methyltransferase (O(6)-MGMT), P-glycoprotein (Pgp), and multidrug resistance protein-1 (MRP-1) in 23 glioblastomas using RT-PCR, methylation-specific PCR, and immunohistochemistry, and analyzed their association with overall patient survival. Univariate analysis of collected data demonstrated that the expressions of O(6)-MGMT and MRP-1 detected by immunohistochemistry, in addition to the consistent factors, including preoperative Karnofsky performance scale (KPS), radical surgery, and tumor location and extension, were significant prognostic factors for the overall survival (OS) of patients with glioblastoma, who received nimustine (ACNU)-based chemotherapy in association with surgery and radiotherapy. Among them, following multivariate analysis, preoperative KPS, radical surgery, tumor location, and the expression of O(6)-MGMT remained as significant prognostic factors. These findings suggest that immunohistochemical analysis of O(6)-MGMT in patients with glioblastoma can be a useful method to predict the effects of chemotherapy and identify alternative chemotherapeutic regimens for O(6)-MGMT-positive patients.

摘要

我们使用 RT-PCR、甲基化特异性 PCR 和免疫组织化学方法研究了 23 例胶质母细胞瘤中 O(6)-甲基鸟嘌呤-DNA 甲基转移酶 (O(6)-MGMT)、P-糖蛋白 (Pgp) 和多药耐药蛋白 1 (MRP-1) 的表达,并分析了它们与患者总生存的关系。对收集的数据进行单因素分析表明,免疫组织化学检测到的 O(6)-MGMT 和 MRP-1 的表达,除了包括术前卡氏功能状态评分 (KPS)、根治性手术、肿瘤位置和扩展等一致因素外,还是接受尼莫司汀 (ACNU) 为基础的化疗联合手术和放疗的胶质母细胞瘤患者总生存率 (OS) 的显著预后因素。其中,多因素分析后,术前 KPS、根治性手术、肿瘤位置和 O(6)-MGMT 的表达仍然是显著的预后因素。这些发现表明,胶质母细胞瘤患者 O(6)-MGMT 的免疫组织化学分析可以作为预测化疗效果的一种有用方法,并为 O(6)-MGMT 阳性患者确定替代化疗方案。

相似文献

1
Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.胶质母细胞瘤中 O6-甲基鸟嘌呤-DNA 甲基转移酶、P-糖蛋白和多药耐药蛋白 1 的免疫组织化学表达的预后意义。
Neuropathology. 2009 Aug;29(4):379-88. doi: 10.1111/j.1440-1789.2008.00983.x. Epub 2008 Nov 19.
2
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.通过启动子高甲基化和免疫组化表达测定的O6-甲基鸟嘌呤-DNA甲基转移酶在间变性胶质瘤中的预后意义
Clin Cancer Res. 2005 Jul 15;11(14):5167-74. doi: 10.1158/1078-0432.CCR-05-0230.
3
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.O6-甲基鸟嘌呤-DNA甲基转移酶沉默对接受手术和卡莫司汀晶片植入的复发性多形性胶质母细胞瘤患者的预后影响:一项前瞻性患者队列研究
Cancer. 2009 Oct 15;115(20):4783-94. doi: 10.1002/cncr.24546.
4
Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.MGMT 基因启动子甲基化状态不能预测替莫唑胺联合顺铂治疗胶质母细胞瘤患者的临床结局。
Neuropathology. 2009 Aug;29(4):443-9. doi: 10.1111/j.1440-1789.2008.00998.x. Epub 2009 Jan 6.
5
Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.O6-甲基鸟嘌呤-DNA甲基转移酶的甲基化以及19号染色体长臂和/或17号染色体短臂杂合性缺失是生存期延长的继发性胶质母细胞瘤的重叠特征。
Clin Cancer Res. 2007 May 1;13(9):2606-13. doi: 10.1158/1078-0432.CCR-06-2184.
6
Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations.软组织肉瘤中O6-甲基鸟嘌呤-DNA甲基转移酶的失活:与K-ras突变的关联。
Hum Pathol. 2009 Jul;40(7):934-41. doi: 10.1016/j.humpath.2009.01.005. Epub 2009 Apr 7.
7
Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.弥漫性星形细胞瘤中MGMT表达评估及其与生存相关性的陷阱:一种可行免疫组化方法的建议
Acta Neuropathol. 2008 Feb;115(2):249-59. doi: 10.1007/s00401-007-0310-x. Epub 2007 Oct 27.
8
Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.脑胶质瘤中 O(6)-甲基鸟嘌呤-DNA 甲基转移酶 MGMT 的转录后调控。
Cancer Biomark. 2011;10(3-4):185-93. doi: 10.3233/CBM-2012-0245.
9
O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.O6-甲基鸟嘌呤-DNA甲基转移酶表达与儿童恶性胶质瘤的预后密切相关:CCG-945队列研究结果
J Clin Oncol. 2006 Jul 20;24(21):3431-7. doi: 10.1200/JCO.2006.05.7265.
10
Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.CD151 在初诊脑胶质母细胞瘤中的预后意义。
J Surg Oncol. 2013 May;107(6):646-52. doi: 10.1002/jso.23249. Epub 2012 Aug 23.

引用本文的文献

1
The impact of ATP-binding cassette transporters in the diseased brain: Context matters.三磷酸腺苷结合盒转运蛋白在病变大脑中的作用:具体情况具体分析。
Cell Rep Med. 2024 Jun 18;5(6):101609. doi: 10.1016/j.xcrm.2024.101609.
2
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.靶向 MALAT1 的 siRNA 纳米复合物使胶质母细胞瘤对替莫唑胺敏感。
Nucleic Acids Res. 2018 Feb 16;46(3):1424-1440. doi: 10.1093/nar/gkx1221.
3
APNG as a prognostic marker in patients with glioblastoma.APNG作为胶质母细胞瘤患者的预后标志物。
PLoS One. 2017 Jun 29;12(6):e0178693. doi: 10.1371/journal.pone.0178693. eCollection 2017.
4
MGMT testing allows for personalised therapy in the temozolomide era.甲基化鸟嘌呤-DNA甲基转移酶(MGMT)检测使得在替莫唑胺时代能够实现个性化治疗。
Tumour Biol. 2016 Jan;37(1):87-96. doi: 10.1007/s13277-015-4240-2. Epub 2015 Oct 30.
5
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.胶质母细胞瘤细胞系中的替莫唑胺耐药性:MGMT、错配修复、P-糖蛋白和CD133表达的影响
PLoS One. 2015 Oct 8;10(10):e0140131. doi: 10.1371/journal.pone.0140131. eCollection 2015.
6
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).O6-甲基鸟嘌呤-DNA甲基转移酶表达的调控与胶质母细胞瘤的治疗(综述)
Int J Oncol. 2015 Aug;47(2):417-28. doi: 10.3892/ijo.2015.3026. Epub 2015 May 29.
7
Role of receptor tyrosine kinases and their ligands in glioblastoma.受体酪氨酸激酶及其配体在胶质母细胞瘤中的作用。
Cells. 2014 Apr 4;3(2):199-235. doi: 10.3390/cells3020199.
8
Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. runt 相关转录因子 3 的缺失诱导胰腺癌对吉西他滨产生耐药性。
Mol Oncol. 2013 Aug;7(4):840-9. doi: 10.1016/j.molonc.2013.04.004. Epub 2013 Apr 23.
9
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.O6-甲基鸟嘌呤-DNA 甲基转移酶蛋白表达和启动子甲基化的联合分析为胶质母细胞瘤的预后提供了优化的预测。
Neuro Oncol. 2013 Mar;15(3):370-81. doi: 10.1093/neuonc/nos308. Epub 2013 Jan 17.
10
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.MGMT 启动子甲基化状态和 MGMT 及 CD133 免疫组化表达作为替莫唑胺联合放疗治疗胶质母细胞瘤患者的预后标志物。
J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.